Here’s our fortnightly wrap of all the news driving ASX health stocks.

Of the ASX’s 134-odd small cap health stocks, 51 saw their share prices fall, 73 improved and 15 were flat.

The top mover was G Medical (ASX:GMV), which has finally begun following through on long delayed deals, and this has been reflected in its share price.

The company completed the clinical trials required to obtain National Medical Products Administration (NMPA) approval for the use of its Prizma device in China.

It’s also secured Taiwan Food and Drug Administration approval, and partner First Channel has until April 4 to provide ancillary Prizma product information such as packaging and labelling to allow it to collect the licence.

G Medical announced deals in 2017 with several distribution partners for the Prizma device that forecast more than $US168m ($245.5m) worth of revenue in the first year of operation.

But delays in getting Chinese manufacturing approval and then doing the requisite clinical trials needed to have a product approved in that country led to the ASX in October asking when, if ever, investors might see this money.

The Silverlake deal for China and the MEDTL deal for Cyprus relied on regulatory approval in China for manufacturing.

First Channel was to supply India and Taiwan and was reliant on finding appropriate partners.

G Medical said at the time all agreements were still current.

Code Name Price (Jan 22) 2 week return % 1 year return % Market cap
GMV G MEDICAL INNOVATION HOLDING 0.155 85 -43 $63,381,604
GTG GENETIC TECHNOLOGIES LTD 0.01 67 34 $40,631,340
CAN CANN GROUP LTD 1.54 61 -31 $219,329,984
MDR MEDADVISOR LTD 0.57 61 120 $140,186,400
EXL ELIXINOL GLOBAL LTD 1.135 53 -60 $156,509,824
BXN BIOXYNE LTD 0.02 33 -26 $12,802,908
ANR ANATARA LIFESCIENCES LTD 0.335 26 -22 $16,701,819
PNV POLYNOVO LTD 2.55 26 315 $1,685,774,464
IHL IMPRESSION HEALTHCARE LTD 0.075 25 257 $53,056,196
NC6 NANOLLOSE LTD 0.065 25 -46 $4,875,000
AVE AVECHO BIOTECHNOLOGY LTD 0.005 25 25 $7,887,287
SKN SKIN ELEMENTS LTD 0.016 23 -36 $2,599,421
UCM USCOM LTD 0.14 22 0 $20,928,302
SCU STEMCELL UNITED LTD 0.017 21 -23 $10,907,342
AC8 AUSCANN GROUP HOLDINGS LTD 0.35 21 -50 $110,966,576
ATX AMPLIA THERAPEUTICS LTD 0.08 19 -43 $4,253,647
PAR PARADIGM BIOPHARMACEUTICALS 3.66 18 226 $723,889,792
AVH AVITA MEDICAL LTD 0.735 18 513 $1,556,343,552
FTT FACTOR THERAPEUTICS LTD 0.0035 17 75 $3,649,925
MDC MEDLAB CLINICAL LTD 0.36 16 -10 $83,959,848
RAP RESAPP HEALTH LTD 0.3 15 200 $208,876,656
ESE ESENSE-LAB LTD-CDI 0.015 15 -46 $2,851,154
NXS NEXT SCIENCE LTD 2.24 15 $403,335,200
ADO ANTEOTECH LTD 0.031 15 91 $46,323,528
BLT BENITEC BIOPHARMA LTD 0.04 14 -60 $12,851,481
M7T MACH7 TECHNOLOGIES LTD 0.76 14 280 $138,838,672
OPT OPTHEA LTD 3.37 14 341 $907,061,696
ADR ADHERIUM LTD 0.033 14 -3 $6,470,043
ALC ALCIDION GROUP LTD 0.21 14 367 $208,045,744
LSH LIFESPOT HEALTH LTD 0.034 13 -55 $2,637,335
CPH CRESO PHARMA LTD 0.185 12 -66 $32,211,692
MXC MGC PHARMACEUTICALS LTD 0.038 12 -5 $52,102,664
THC THC GLOBAL GROUP LTD 0.43 12 -11 $60,530,904
IMM IMMUTEP LTD 0.295 11 -7 $115,531,128
ZLD ZELIRA THERAPEUTICS LTD 0.061 11 9 $53,219,036
PAB PATRYS LTD 0.021 11 -13 $22,524,396
NEU NEUREN PHARMACEUTICALS LTD 2.83 10 102 $291,971,168
IDT IDT AUSTRALIA LTD 0.165 10 14 $39,097,268
CGS COGSTATE LTD 0.5 10 -16 $84,127,496
IPD IMPEDIMED LTD 0.17 10 -14 $86,878,384
BIT BIOTRON LTD 0.06 9 -52 $42,115,964
SDX SIENNA CANCER DIAGNOSTICS LT 0.04 8 -33 $15,805,314
AHX APIAM ANIMAL HEALTH LTD 0.47 8 1 $54,465,668
PIQ PROTEOMICS INTERNATIONAL LAB 0.3 7 -20 $27,564,262
TDL TBG DIAGNOSTICS LTD 0.032 7 -27 $6,962,793
CP1 CANNPAL ANIMAL THERAPEUTICS 0.16 7 23 $14,900,000
OSL ONCOSIL MEDICAL LTD 0.17 6 -6 $107,220,496
PBP PROBIOTEC LTD 2.15 6 46 $160,774,576
GSS GENETIC SIGNATURES LTD 1.02 6 29 $145,171,248
MEM MEMPHASYS LTD 0.056 6 84 $42,222,536
LCT LIVING CELL TECHNOLOGIES LTD 0.019 6 -60 $10,857,379
MVP MEDICAL DEVELOPMENTS INTERNA 9.33 5 135 $612,115,840
ATH ALTERITY THERAPEUTICS LTD 0.02 5 -46 $17,847,400
PYC PYC THERAPEUTICS LTD 0.065 5 132 $190,542,816
HLA HEALTHIA LTD 1.13 5 5 $71,229,160
TD1 TALI DIGITAL LTD 0.05 4 61 $37,465,260
SDI SDI LTD 0.885 4 43 $105,195,992
DVL DORSAVI LTD 0.027 4 -58 $5,888,543
DXB DIMERIX LTD 0.14 4 61 $25,413,740
CDX CARDIEX LTD 0.029 4 -42 $21,843,070
ICS ICSGLOBAL LTD 1.905 4 121 $20,200,656
AGH ALTHEA GROUP HOLDINGS LTD 0.465 3 66 $108,489,152
MMJ MMJ GROUP HOLDINGS LTD 0.155 3 -40 $34,781,844
OCC ORTHOCELL LTD 0.49 3 250 $90,333,832
ACW ACTINOGEN MEDICAL LTD 0.037 3 -36 $41,411,560
1ST 1ST GROUP LTD 0.08 3 220 $33,969,352
CDY CELLMID LTD 0.23 2 -16 $22,217,280
RAC RACE ONCOLOGY LTD 0.23 2 153 $25,103,328
CYC CYCLOPHARM LTD 1.3 2 17 $101,709,920
CTE CRYOSITE LTD 0.054 2 20 $2,530,417
SUD SUDA PHARMACEUTICALS LTD 0.06 2 -49 $8,535,264
HCT HOLISTA COLLTECH LTD 0.08 1 38 $18,753,926
NVL NATIONAL VETERINARY CARE LTD 3.66 1 105 $245,738,352
KZA KAZIA THERAPEUTICS LTD 0.625 1 49 $45,104,172
PSQ PACIFIC SMILES GROUP LTD 1.76 1 35 $267,508,368
CYP CYNATA THERAPEUTICS LTD 1.2 0 -11 $123,621,784
CAJ CAPITOL HEALTH LTD 0.23 0 -7 $176,731,872
MEB MEDIBIO LTD 0.01 0 -47 $9,951,300
ALT ANALYTICA LTD 0.003 0 -40 $10,558,837
BPH BPH ENERGY LTD 0.001 0 -33 $3,341,463
GLH GLOBAL HEALTH LTD 0.145 0 -14 $6,104,257
JHL JAYEX HEALTHCARE LTD 0.03 0 11 $5,178,391
ONE ONEVIEW HEALTHCARE PLC-CDI 0.12 0 -77 $20,785,378
IMU IMUGENE LTD 0.035 0 75 $154,908,976
ONT 1300 SMILES LTD 6.1 0 2 $144,438,144
JHC JAPARA HEALTHCARE LTD 0.995 -1 -10 $265,911,088
MVF MONASH IVF GROUP LTD 1.02 -1 15 $240,501,600
PGC PARAGON CARE LTD 0.43 -1 -25 $145,290,672
RCE RECCE PHARMACEUTICALS LTD 0.36 -1 140 $48,335,060
AZV AZURE HEALTHCARE LTD 0.083 -2 46 $23,587,682
AMT ALLEGRA ORTHOPAEDICS LTD 0.2 -2 0 $19,911,810
ELX ELLEX MEDICAL LASERS LTD 0.76 -3 27 $109,136,864
ACR ACRUX LTD 0.18 -3 -10 $30,040,040
KKT KONEKT LTD 0.65 -3 159
SOM SOMNOMED LTD 2.77 -3 53 $173,967,552
MX1 MICRO-X LTD 0.165 -3 -38 $41,253,376
PAA PHARMAUST LTD 0.091 -3 139 $27,483,916
IMC IMMURON LTD 0.13 -4 -48 $23,038,392
VHT VOLPARA HEALTH TECHNOLOGIES 1.79 -4 45 $390,792,768
RHT RESONANCE HEALTH LTD 0.25 -4 153 $107,720,984
BWX BWX LTD 4.31 -4 177 $535,517,024
S66 STAR COMBO PHARMA LTD 0.46 -4 -17 $39,806,836
EHH EAGLE HEALTH HOLDINGS LTD 0.115 -4 -41 $38,365,908
RNO RHINOMED LTD 0.18 -5 -18 $30,457,082
RGS REGENEUS LTD 0.072 -5 -54 $20,003,400
PAL PALLA PHARMA LTD 1.005 -6 -14 $126,577,720
BD1 BARD1 LIFE SCIENCES LTD 0.032 -6 40 $43,749,920
NTI NEUROTECH INTERNATIONAL LTD 0.016 -6 -61 $2,171,902
LBT LBT INNOVATIONS LTD 0.16 -6 88 $37,686,364
PTX PRESCIENT THERAPEUTICS LTD 0.056 -7 -17 $22,078,596
VBS VECTUS BIOSYSTEMS LTD 0.55 -7 10 $13,010,149
TLX TELIX PHARMACEUTICALS LTD 1.49 -7 96 $377,387,200
PXS PHARMAXIS LTD 0.135 -7 -50 $53,280,748
OSP OSPREY MEDICAL INC-CDI 0.027 -7 -77 $11,658,529
BOT BOTANIX PHARMACEUTICALS LTD 0.093 -7 21 $90,460,920
OSX OSTEOPORE LTD 0.66 -7 $66,812,132
OIL OPTISCAN IMAGING LTD 0.036 -8 -18 $17,200,036
UBI UNIVERSAL BIOSENSORS INC-CDI 0.17 -8 -23 $30,166,676
APH AUSTRALIAN PRIMARY HEMP LTD 0.165 -8 3 $11,472,472
IVX INVION LTD 0.011 -8 -39 $60,506,668
VLS VITA LIFE SCIENCES LTD 0.65 -8 -16 $36,131,716
ANP ANTISENSE THERAPEUTICS LTD 0.075 -9 108 $36,658,896
IBX IMAGION BIOSYSTEMS LTD 0.03 -9 -6 $15,338,466
BNO BIONOMICS LTD 0.077 -9 -38 $41,940,812
FFC FARMAFORCE LTD 0.09 -10 -25 $11,589,388
RSH RESPIRI LTD 0.08 -10 -8 $44,500,648
PCK PAINCHEK LTD 0.175 -10 430 $181,216,416
NOX NOXOPHARM LTD 0.255 -11 -45 $33,711,048
CMP COMPUMEDICS LTD 0.7 -11 106 $124,014,064
SVA SIMAVITA LTD-CDI 0.03 -12 58 $12,533,344
1AD ADALTA LTD 0.095 -14 -59 $15,574,833
OVN OVENTUS MEDICAL LTD 0.425 -15 41 $55,475,128
NSB NEUROSCIENTIFIC BIOPHARMACEU 0.165 -15 14 $12,933,456
RHY RHYTHM BIOSCIENCES LTD 0.105 -16 -22 $10,578,750
VTI VISIONEERING TECH-CDI 0.041 -16 -77 $19,097,874
SIL SMILES INCLUSIVE LTD 0.052 -28 -80 $6,928,775

MedAdvisor (ASX:MDR) has signed its second US agreement to provide medication education programs for a top 10 pharmaceutical company.

It did not disclose the name of that company.

It will hold four, nine-month-long digital health pilot programs offering digital education to patients on any one of four different medications over the next 12 months.

Patients will be drawn from up to 4,000 US pharmacies starting in the third quarter of fiscal 2020 and the revenue attributable to MedAdvisor is about $825,000.

“These initial pilot programs represent the first material revenue from the US expansion and an important milestone in the commercialisation and scale of the US market opportunity,” the company said.

The initial program equates to 80 per cent of the total revenue from Australian health programs in fiscal 2019.

Anatara Lifesciences (ASX:ANR) says in vitro and in vivo preclinical data reported for its Gastrointestinal ReProgramming (GaRP) dietary supplement has been positive and it is confident of launching a human clinical study this year.

Anatara believes its GaRP supplement may be the “breakthrough product so desperately needed by patients suffering chronic bowel conditions”, such as irritable bowel syndrome and inflammatory bowel disease.

The company has data supporting the formulation’s ability to combat the three underlying causes of chronic bowel conditions, such as reducing gut inflammation by significantly reducing the production of pro-inflammatory proteins and promoting healing of the gut lining by increasing mucin genes.

Medlab Clinical (ASX:MDC) provided a market update, saying it made record quarterly revenue from cannabis sales, with an increase of approximately 50 per cent over the previous best quarter and 400 per cent over the previous corresponding period.

It also said the Royal North Shore Hospital (RNSH) clinical trial had been completed and it was awaiting results, but the initial feedback was encouraging.

And approximately 120 Australian doctors and 230 patients have been recruited for a trial on cancer pain drug Nanabis.

Managing director Dr Sean Hall said the nutraceuticals business was expanding into new revenue territories including the US, UK and Asia and they should see revenue flow over the next few months without material operating or capital expenditure.

“We also have licensing opportunities for our NanoCelle delivery platform,” he said.